ProShares - UltraShort Nasdaq Biotechnology (BIS) Volatility Skew
Implied volatility skew shows how IV varies across strike prices for a given expiration. Steeper skews indicate higher demand for downside protection relative to upside speculation.
ProShares - UltraShort Nasdaq Biotechnology (BIS) operates in the Financial Services sector, specifically the Asset Management industry, with a market capitalization near $2.4M, listed on NASDAQ, carrying a beta of -1.20 to the broader market. ProShares UltraShort Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index. public since 2010-04-09.
Snapshot as of May 15, 2026.
- Spot Price
- $8.76
- ATM IV
- 50.0%
- IV Skew 25Δ
- 0.007
- IV Rank
- 10.9%
- IV Percentile
- 61.5%
- Term Structure Slope
- 0.374
As of May 15, 2026, ProShares - UltraShort Nasdaq Biotechnology (BIS) at-the-money implied volatility is 50.0%. IV rank is 10.9% (where 0% is the 52-week low and 100% is the 52-week high). IV percentile is 61.5%. The 25-delta skew is +0.007: skew is roughly flat across the 25-delta wings. High IV rank typically favors premium-selling strategies; low IV rank favors premium-buying.
BIS Strategy Selection at Current Volatility Levels
For ProShares - UltraShort Nasdaq Biotechnology options at 50.0% ATM IV, low IV rank (10.9%) favors premium-buying or long-vol structures: long calls or puts, debit spreads, calendar spreads, long straddles. The risk: low-rank regimes can persist for months while time decay eats premium-buyers alive. Pair the vol-rank read with the dealer-gamma view and the upcoming-events calendar to confirm the strategy fits both the structural regime and the path-dependent risk. The variance risk premium - the persistent gap between implied and subsequently realized vol - is positive in equity markets on average; high IV rank typically reflects a stretch where the premium is wider than usual.
Learn how volatility skew is reported and how to read the data →
Frequently asked BIS volatility skew questions
- What is the current BIS ATM implied volatility?
- As of May 15, 2026, ProShares - UltraShort Nasdaq Biotechnology (BIS) at-the-money implied volatility is 50.0%. IV rank is 10.9% on a 0-100% scale anchored to the 1-year IV range. ATM IV is the volatility input that makes a Black-Scholes-equivalent model reproduce the listed at-the-money option prices.
- Is BIS IV high or low historically?
- IV is subdued relative to its 1-year history, conditions that typically favor premium-buying strategies (long calls, long puts, debit spreads, calendar spreads).
- What does BIS volatility skew tell options traders?
- Volatility skew is the pattern by which IV varies across strikes for a given expiration. ProShares - UltraShort Nasdaq Biotechnology skew is roughly flat across the 25-delta wings. Skew matters for risk-defined strategy selection: when downside puts are rich, put-credit spreads capture more premium; when upside calls are rich, call-credit spreads or covered-call writes harvest more.